Logo image of CERO

CERO THERAPEUTICS HOLDINGS I (CERO) Stock Overview

USA - NASDAQ:CERO - US71902K4022 - Common Stock

5.32 USD
-0.07 (-1.3%)
Last: 10/7/2025, 4:07:21 PM
5.23 USD
-0.09 (-1.69%)
After Hours: 10/7/2025, 4:07:21 PM

CERO Key Statistics, Chart & Performance

Key Statistics
52 Week High895.4
52 Week Low4.27
Market Cap6.44M
Shares1.21M
Float1.17M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-223.77
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO10-06 2021-10-06
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


CERO short term performance overview.The bars show the price performance of CERO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -20 -40 -60

CERO long term performance overview.The bars show the price performance of CERO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of CERO is 5.32 USD. In the past month the price increased by 9.02%. In the past year, price decreased by -97.2%.

CERO THERAPEUTICS HOLDINGS I / CERO Daily stock chart

CERO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 21.99 411.31B
AMGN AMGEN INC 13.55 159.11B
GILD GILEAD SCIENCES INC 15.09 144.90B
VRTX VERTEX PHARMACEUTICALS INC 24.22 105.19B
REGN REGENERON PHARMACEUTICALS 12.78 61.82B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 60.24B
ARGX ARGENX SE - ADR 86.01 48.80B
ONC BEONE MEDICINES LTD-ADR 5.52 37.52B
INSM INSMED INC N/A 34.31B
BNTX BIONTECH SE-ADR N/A 25.50B
NTRA NATERA INC N/A 23.13B
BIIB BIOGEN INC 9.51 22.32B

About CERO

Company Profile

CERO logo image CERo Therapeutics Holdings, Inc. is an immunotherapy company, which engages in development of engineered T cell therapeutics for the treatment of cancer. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. This novel cellular immunotherapy platform is designed to redirect patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating what the Company refers to as Chimeric Engulfment Receptor T cells (CER-T). Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand. The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.

Company Info

CERO THERAPEUTICS HOLDINGS I

201 Haskins Way, Suite 230

South San Francisco CALIFORNIA US

Employees: 8

CERO Company Website

CERO Investor Relations

Phone: 6504072376

CERO THERAPEUTICS HOLDINGS I / CERO FAQ

What is the stock price of CERO THERAPEUTICS HOLDINGS I today?

The current stock price of CERO is 5.32 USD. The price decreased by -1.3% in the last trading session.


What is the ticker symbol for CERO THERAPEUTICS HOLDINGS I stock?

The exchange symbol of CERO THERAPEUTICS HOLDINGS I is CERO and it is listed on the Nasdaq exchange.


On which exchange is CERO stock listed?

CERO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CERO THERAPEUTICS HOLDINGS I stock?

8 analysts have analysed CERO and the average price target is 45.9 USD. This implies a price increase of 762.78% is expected in the next year compared to the current price of 5.32. Check the CERO THERAPEUTICS HOLDINGS I stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CERO THERAPEUTICS HOLDINGS I worth?

CERO THERAPEUTICS HOLDINGS I (CERO) has a market capitalization of 6.44M USD. This makes CERO a Nano Cap stock.


How many employees does CERO THERAPEUTICS HOLDINGS I have?

CERO THERAPEUTICS HOLDINGS I (CERO) currently has 8 employees.


What are the support and resistance levels for CERO THERAPEUTICS HOLDINGS I (CERO) stock?

CERO THERAPEUTICS HOLDINGS I (CERO) has a support level at 5.27 and a resistance level at 5.33. Check the full technical report for a detailed analysis of CERO support and resistance levels.


Should I buy CERO THERAPEUTICS HOLDINGS I (CERO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CERO THERAPEUTICS HOLDINGS I (CERO) stock pay dividends?

CERO does not pay a dividend.


What is the Price/Earnings (PE) ratio of CERO THERAPEUTICS HOLDINGS I (CERO)?

CERO THERAPEUTICS HOLDINGS I (CERO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-223.77).


What is the Short Interest ratio of CERO THERAPEUTICS HOLDINGS I (CERO) stock?

The outstanding short interest for CERO THERAPEUTICS HOLDINGS I (CERO) is 9.08% of its float. Check the ownership tab for more information on the CERO short interest.


CERO Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to CERO. When comparing the yearly performance of all stocks, CERO is a bad performer in the overall market: 98.97% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CERO Financial Highlights

Over the last trailing twelve months CERO reported a non-GAAP Earnings per Share(EPS) of -223.77. The EPS increased by 63.38% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -675.76%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%71.35%
Sales Q2Q%N/A
EPS 1Y (TTM)63.38%
Revenue 1Y (TTM)N/A

CERO Forecast & Estimates

8 analysts have analysed CERO and the average price target is 45.9 USD. This implies a price increase of 762.78% is expected in the next year compared to the current price of 5.32.


Analysts
Analysts82.5
Price Target45.9 (762.78%)
EPS Next Y90.59%
Revenue Next YearN/A

CERO Ownership

Ownership
Inst Owners20.48%
Ins Owners2.67%
Short Float %9.08%
Short Ratio0.66